Background: Maraviroc-containing regimens are known to achieve virological suppression in many treatmentexperienced patients. This study aimed to evaluate a more rigorous methodological approach to resistance-response analysis in large clinical studies and to better establish which subpopulations of patients were most likely to benefit from maraviroc by refining and extending previous subgroup analyses from the MOTIVATE studies. Methods: Individual weighted optimized background therapy (OBT) susceptibility scores were calculated by combining genotypic or phenotypic resistance testing with prior drug use information. Virological response (HIV-1 RNA<50 copies/ml at week 48) using each of these methods was compared with a commonly used method of counting active drugs. Baseline predictors of virological response, including weighted or unweighted scoring, maraviroc use, baseline
Maraviroc is an orally available antagonist that binds to the chemokine receptor CCR5 and prevents its interaction with the HIV-1 envelope [1] . Maraviroc is approved for twice-daily administration in the combination treatment of CCR5-tropic HIV-1 infection. The clinical efficacy of maraviroc was initially established in treatment-experienced patients in two Phase III clinical studies: MOTIVATE 1 (Maraviroc plus Optimized Therapy In Viraemic Antiretroviral TreatmentExperienced patients 1) in the USA and Canada, and MOTIVATE 2 in Europe, Australia and the USA. In both studies, treatment-experienced patients with a CCR5 (R5) screening tropism result were randomized to receive maraviroc (once or twice daily) or placebo along with an optimized background therapy (OBT) of 3-6 approved agents. Individual and pooled analyses from these studies showed significantly greater virological and immunological responses over 48 weeks
Original article
Baseline CD4 + T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients Introduction in patients receiving maraviroc compared with those receiving placebo [2, 3] .
Subgroup analyses have established that simple binary susceptibility estimates of OBT regimen activity, maraviroc use, viral load, CD4 + T-cell count and the first use of enfuvirtide or selected protease inhibitors (PIs) as fully active new agents are associated with virological outcome in the MOTIVATE studies [4] . These data are consistent with other treatment-experienced patient studies of the association between the number of active drugs and the rate of virological response [5, 6] .
The commonly used approach to estimating regimen activity in treatment-experienced patient studies, including the MOTIVATE subanalyses described above, has several limitations. In the binary assignation, active agents with full susceptibility are coded as 1, whereas any reduced susceptibility is coded as 0. Regimen activity scores are typically derived by counting all coadministered agents deemed active by resistance testing. This approach implicitly assumes an equal contribution by each active agent towards the total antiviral activity of the regimen. This is not always the case, as recycled but active nucleoside reverse transcriptase inhibitors (NRTIs) contribute less to the antiviral activity of a regimen than active agents from other classes [7] [8] [9] . Moreover, agents that experience a cumulative loss of susceptibility over a wide dynamic range, such as protease inhibitors (PIs), might exhibit significant partial activity. In addition, for patients with detectable baseline viraemia on a pre-study regimen, scoring agents carried forward from the failing regimen into the study regimen will confound correlations with on-study virological responses, given that such agents are unlikely to contribute to post-baseline reductions in plasma HIV-1 RNA. Finally, alterations to regimen composition over the period of active on-study therapy are seldom controlled for in activity-response analyses that score the initial set of drugs received. Resistance-response studies are important for establishing the activity of new agents as a function of pre-existing resistance to older companion drugs. However, the result of these methodological problems is that the clinical datasets used in such analyses are seldom 'clean' and the final response outcome will in part be determined by associations with hidden covariates not included in the evaluation.
Current treatment guidelines for treatmentexperienced patients recommend maximally suppressing HIV RNA levels (for example, to <50 copies/ml) and to prevent further selection of resistance mutations [10] : two goals that are intimately linked. New regimens should include at least two, and preferably three, fully active agents that should include new antiretroviral drugs, including some with new mechanisms of action [10] . With the availability of four agents active against multidrug-resistant HIV (maraviroc, raltegravir, darunavir and etravirine) over the past few years, questions exist regarding how many agents are needed for complete virological control in treatmentexperienced patients, which patients have the highest probability of response and whether a more rigorous method of assessing regimen activity might improve patient management by more accurately establishing the predictive associations between baseline conditions and virological outcome. The availability of both genotypic and phenotypic methodologies for assessing drug activity also raises the question as to whether one approach correlates better with response than the other.
We have undertaken a post-hoc analysis on pooled data from the MOTIVATE studies in which we compare week 48 virological outcomes for a standard 'drug counting' approach to estimating regimen activity versus a weighted system based on both genotypic and phenotypic resistance testing.
Methods

MOTIVATE study population
MOTIVATE 1 and 2 (ClinicalTrials.gov numbers NCT00098306 and NCT00098722, respectively) enrolled treatment-experienced adults (89% male and 84% White) with exclusively CCR5-tropic (R5) HIV-1, plasma viraemia ≥5,000 RNA copies/ml at screening and either ≥6 months prior experience of antiretroviral agents from at least three classes (NRTIs, non-nucleoside reverse transcriptase inhibitors [NNRTIs], PIs and enfuvirtide) or documented HIV-1 resistance to ≥3 of these classes. The design and 48-week outcome of these studies have been described elsewhere [3] . Raltegravir, etravirine and darunavir were not permitted in the OBT. Tipranavir was initially excluded, but was later allowed following the availability of maraviroc drug interaction data. The pooled study population was mostly (93.6% [982/1,049]) infected with subtype B HIV-1.
Analysis populations
The analysis populations were defined to minimize confounding by non-virological failures and on-study regimen changes and their derivation is shown in Figure 1 . Briefly, patients were included in this analysis if they had a complete resistance and tropism testing dataset available at screening, achieved a virological outcome (defined by time to loss of virological response; see Statistical analyses) by week 48 [11] , began their OBT regimen within a 7-day window of their 'day 1' baseline study visit (that is, day -6 to +7) and remained on an unchanged drug regimen during the entire treatment phase. As not all patients possessed both genotypic and phenotypic drug resistance data at baseline, three analysis populations were derived from the full analysis set of 1,049 patients in MOTIVATE 1 and 2 by application of the above selection criteria: a genotype population of patients with genotypic resistance data (n=604), a phenotype population with phenotype data (n=631) and a combined genotype/phenotype population with both (n=598). For the logistic regression analysis described below, one patient who lacked complete baseline covariate data was excluded from all three of the analysis populations described to yield modelling populations of 603, 630 and 597 patients, respectively ( Figure  1 ). Of note, all patients (n=145) who discontinued the study over 48 weeks for non-virological failures such as adverse events or loss to follow-up were excluded.
Scoring methodologies
Two weighted and one unweighted OBT scoring methods were defined, based on OBT drug susceptibilities assessed in screening visit samples. All three scores excluded maraviroc (which as a new drug class is assumed to be fully active) and ritonavir when it was used at subtherapeutic doses to boost other PIs. Reverse transcriptase and protease sequencing and phenotypic resistance testing were performed by Monogram Biosciences (South San Francisco, CA, USA). All three scoring methods used gp41
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Figure 1. Patients included in the analyses
ARV, antiretroviral; g-VO, genotypic virological outcome; g-wOBTSS, genotypic weighted optimized background therapy sensitivity score; OBT, optimized background therapy; OSS, overall susceptibility score; p-VO, phenotypic virological outcome; p-wOBTSS, phenotypic weighted optimized background therapy sensitivity score.
genotypic sequencing alone (BC Centre for Excellence in HIV/AIDS, Vancouver, Canada) to determine susceptibility to enfuvirtide. Tropism was determined at the screening and baseline visits using the original Trofile™ assay (Monogram Biosciences). Unweighted scoring was performed using the overall susceptibility score (OSS), a simple binary drug-counting approach used as the major protocol-specified assessment of OBT activity in the MOTIVATE studies in previous subgroup analyses [4] . The OSS was defined as the sum of all OBT drugs received to which the patient's virus was interpreted as susceptible. For antiretroviral agents other than enfuvirtide, susceptibility was defined by a combination of phenotypic and genotypic data according to a proprietary methodology ('PhenoSense GT'; Monogram Biosciences) used to generate the screening resistance test reports provided to MOTIVATE investigators. To assess the influence of recycling drugs from the failing, pre-study regimen, drugs from these regimens that were continued into the OBT were included in the OSS if there was no evidence of resistance. All drugs with full susceptibility contributed 1 point, whereas drugs with any reduced susceptibility were coded as 0 [4] .
Weighted optimized background therapy sensitivity scores (wOBTSS) were derived using either phenotypic (p-wOBTSS) or genotypic (g-wOBTSS) resistance testing in the appropriate population. Both weighted methodologies excluded OBT drugs recycled from the failing pre-study regimen, scoring them as 0 irrespective of resistance test result. The p-wOBTSS method, which has previously been used to explore antiviral phenotypic cutoffs [12] , used a binary (sensitive/ resistant) classification of susceptibility and scored all OBT agents (other than enfuvirtide) according to phenotypic susceptibility alone (PhenoSense assay; Monogram Biosciences) using the assay-defined lower clinical cutoff for each drug. Unlike the OSS, which also used a binary scoring system, the p-wOBTSS did not assign the same weight to all active agents: active PIs, NNRTIs and enfuvirtide contributed 1.0 to the p-wOBTSS, whereas active NRTIs contributed 0.5.
The g-wOBTSS method used a trinary (sensitive/ intermediate/resistant) classification of susceptibility based on the widely used Agence Nationale de Recherches sur le Sida (ANRS) genotypic algorithm. This trinary classification was used to ascertain whether the additional refinement of acknowledging partial drug activities added predictive value to the weighting method explored. For all agents except unboosted PIs, the 2008 revision of the algorithm was used [13] ; the nevirapine rule was used to score delavirdine (n=1). For unboosted PIs (n=9), the earlier ANRS 2002 algorithm was used [14] . As with the p-wOBTSS, all agents to which the screening virus was ranked as 'sensitive' scored 1.0 except for NRTIs, which scored 0.5. In addition, however, in the g-wOBTSS approach PIs with an 'intermediate' ranking (whether boosted or not) scored 0.5, whereas all other drugs ranked as 'intermediate' scored 0.
Note that although the OSS is a direct estimate of the number of active drugs in an OBT regimen, both the g-wOBTSS and the p-wOBTSS are semi-quantitative estimates of overall regimen activity and do not necessarily correspond to the number of active drugs received.
Statistical analyses
In the published primary efficacy analysis of the MOTIVATE studies, virological response was defined as HIV-1 RNA<50 copies/ml at week 48. For these analyses of outcomes by susceptibility score, virological response at week 48 was defined by the time to loss of virological response algorithm with a threshold for response of <50 copies/ml [15] .
The restrictions on patient inclusion necessary to prevent confounding resulted in the exclusion of a significant proportion (40%) of the overall MOTIVATE patient set. To address the possibility of bias, baseline characteristics (median HIV-1 RNA, CD4 + T-cell count and numbers of resistance mutations) were compared between patients included in and excluded from the final genotypic and phenotypic analysis populations by a two-sample Student's t-test.
Logistic regression analysis was used to assess predictors of virological response for OBT scoring by g-wOBTSS or p-wOBTSS versus OSS. In addition to OBT scores, each model also included the fixed covariates of baseline CD4 + T-cell count (arithmetic mean of screening and baseline visits), baseline viral load (geometric mean of up to three visits at screening, randomization and baseline), baseline tropism (DM/X4 versus R5 and DM/X4 versus unreportable) and treatment (maraviroc once-or twice-daily, combined, versus placebo).
Goodness-of-fit for each model was assessed by the Hosmer and Lemeshow (H&L) test [16] , which generates a χ 2 test statistic for the null hypothesis that the model is correct. A larger P-value for this test implies a better fit. If the H&L P-value is <0.05 this hypothesis is rejected and it can be concluded that the model does not provide a reasonable fit. Figure 2A shows the distribution of OSS and g-wOBTSS results in the genotypic analysis population. The proportions of patients with intermediate scores were broadly comparable between the two methods but, compared with the OSS, use of the g-wOBTSS resulted in a redistribution of patients at very high and very low score strata. The number of patients estimated to be receiving at least three active drugs in their OBT (not counting randomized maraviroc) was sevenfold higher by OSS than g-wOBTSS, whereas the number of patients estimated to be receiving either no active OBT drugs (OSS and g-wOBTSS =0) or only a single active nucleoside (g-wOBTSS =0.5) was 2.5-fold higher by g-wOBTSS.
Results
Weighted versus unweighted scoring
In the placebo arm, where virological response was entirely attributable to OBT activity, this redistribution of patients by score was associated with incremental increases in the proportion of virological responders for increasing levels of regimen activity by g-wOBTSS estimation. By contrast, the proportion of responders remained low and similar for all patients estimated to be receiving fewer than three fully active drugs by OSS ( Figure 2B ). Similar results were observed for the distribution of patients according to p-wOBTSS values relative to OSS in the phenotypic analysis population (DC, data not shown). Figure 3 shows multivariate predictors of virological success in models that contain OSS versus g-wOBTSS scoring ( Figure 3A) or OSS versus p-wOBTSS scoring ( Figure 3B ) in the appropriate genotypic or phenotypic analysis populations. Owing to the low number of patients with weighted scores of three or more (Figure 2) , the highest OBT activity stratum was set to ≥2 for both weighted and unweighted modelling. Keeping other covariates constant, the two wOBTSS models gave a better fit to the data in their respective populations than did the models that incorporated the OSS, as indicated by higher H&L P-values (0.1241 and 0.0936 for g-wOBTSS and OSS, respectively; 0.1570 and 0.0090 for p-wOBTSS and OSS, respectively). Of note, the small H&L P-value for the OSS model in the phenotypic population implies a poor fit ( Figure 3B ).
Increasing OBT susceptibility score (weighted or unweighted), a baseline CD4 + T-cell count ≥50 cells/mm 3 and treatment with maraviroc were the strongest independent predictors of virological response in each model; baseline HIV-1 RNA<100,000 copies/ml was also significant. HIV-1 tropism at baseline visit was not a significant predictor of response in these patients, who had all previously returned an R5 tropism result at their screening visit (original Trofile assay; Monogram Biosciences). Figure 4 shows g-wOBTSS and p-wOBTSS logistic regression models for patients with matched genotype and phenotype data, excluding those who received placebo. The two methods gave similar results for all covariates and baseline tropism remained non-significant even after exclusion of the placebo arms. Similar response rates were seen for genotypic and phenotypic weighted scoring. For example, in the maraviroc twice daily arm, HIV-1 RNA at week 48 was <50 copies/ml in 36%, 54% and 71% of patients with g-wOBTSS of <1, 1 to <2 and ≥2, respectively, and in 33%, 50% and 73% of patients with p-wOBTSS of <1, 1 to <2 and ≥2, respectively. In the subpopulation with baseline CD4 + T-cell counts ≥50 cells/mm 3 , HIV-1 RNA at week 48 was <50 copies/ml in 46%, 62% and 77% of patients with g-wOBTSS of <1, 1 to <2 and ≥2, respectively, and in 42%, 58% and 81% of patients with p-wOBTSS of <1, 1 to <2 and ≥2, respectively.
Genotypic versus phenotypic weighted scoring
Representativeness of the analysis population
Comparisons of baseline characteristics between MOTIVATE patients who were included (n=598) or excluded (n=451) from the combined regression model population are shown in Table 1 . In each treatment arm, included and excluded patients showed similar baseline HIV-1 RNA levels and CD4 + T-cell counts with no evidence of a statistical difference between the two groups (P>0.05 for all comparisons). The median number of major PI mutations, minor PI mutations and thymidine analogue mutations (International Antiviral Society USA 2008) [17] was also very similar between included and excluded patients.
Discussion
Although it is known that maraviroc-containing regimens achieve virological suppression in a substantial proportion of treatment-experienced patients [4, 18] , this post hoc study sought both to evaluate a more rigorous methodological approach to resistance-response analysis in large clinical studies and to better establish which particular subpopulations of patients were most likely to benefit from maraviroc by refining and extending previous subgroup analyses from MOTIVATE [4] .
These additional analyses show that, in a study population defined to minimize confounding, baseline CD4 + T-cell count and a weighted activity scoring of only those background antiretrovirals newly initiated at study baseline were the strongest independent predictors of response to maraviroc in MOTIVATE 1 and 2.
Overall, approximately 70% of MOTIVATE patients receiving maraviroc with a weighted OBT susceptibility score of ≥2 by either phenotypic or genotypic testing achieved <50 HIV-1 RNA copies/ml at 48 weeks. This number rose to approximately 80% for participants who received maraviroc with the equivalent of at least two fully active OBT drugs by either method and who had a baseline CD4 + T-cell count ≥50 cells/mm 3 . However, a reduced virological response was observed in patients with very low CD4 + T-cell counts, consistent with results reported for other antiretroviral drugs, such as enfuvirtide, darunavir, etravirine and raltegravir in their pivotal salvage trials [6, 19] , and consistent with reports that baseline CD4 + T-cell count is an independent predictor of outcome in HIV-infected patients [20, 21] . Odds ratios and 95% confidence intervals for predictors of virological response (HIV-1 RNA<50 copies/ml at week 48) in logistic regression models using (A) genotypic weighted optimized background therapy sensitivity score (g-wOBTSS; square markers) versus overall susceptibility score (OSS; circular markers) and (B) phenotypic weighted optimized background therapy sensitivity score (p-wOBTSS; diamond markers) versus OSS (circular markers). Fractional values were rounded down in both wOBTSS models. Odds ratios and 95% confidence intervals for predictors of virological response (HIV-1 RNA<50 copies/ml at week 48) in patients on maraviroc once or twice daily (n=487) in logistic regression models in the combined model population using genotypic weighted optimized background therapy sensitivity score (g-wOBTSS; square markers) or phenotypic weighted optimized background therapy sensitivity score (p-wOBTSS; diamond markers). a All patients had an R5 tropism result at screening visit. [22] infers that similar observations would result from the use of an alternative platform. It is also interesting that a baseline non-R5 tropism result following a previous R5 screening result was not significantly associated with virological outcome. However, the caveat applies here that this is established only for a relatively small number of patients who probably had low-level CXCR4-using populations that went undetected at screening, and not for patients with established non-R5 infections where maraviroc is known to confer little or no virological benefit [23] . A newer version of the Trofile assay has become available since MOTIVATE trial screening, with greater discrimination for lowlevel non-R5 populations, which would probably have identified and excluded at screening most or all of those patients with non-R5 baseline results in these analyses.
Compared with the weighted methods, the OSS substantially overestimated the numbers receiving a fully active HAART regimen from the OBT alone (OSS≥3) and underestimated those with little or no OBT activity. This finding is consistent with both substantial OBT recycling of 'active' agents from the failing pre-MOTIVATE regimen and with the high use of nucleoside analogues with lower weighted scores. The redistribution of patients with very high and very low OSS values when weighted scoring was used was associated with a much more linear association between virological response and OBT score among those not receiving maraviroc as a new agent. OSS-type scoring is common in resistance-response analyses and correlates with virological outcomes [24, 25] ; our data are consistent with those from studies of darunavir and raltegravir that used OSS-like scoring of OBT activity [5, 6] . However, comparison with the weighted approaches suggests that OSS-like methods lack discrimination and might introduce other sources of confounding.
This study is subject to several limitations. The available resistance data were cross-sectional and based on the results of a single sample at screening visit. These were the data used to guide OBT selection in MOTIVATE and hence the most appropriate data for establishing a link between the drugs chosen and subsequent response in this particular dataset. However, it is known that cross-sectional testing can underestimate the total resistance burden in treatment-experienced patients [26] and that a longitudinal approach incorporating previous test results can improve response to a subsequent regimen [27] . It is therefore unclear whether longitudinal data would have changed the relationship between the resistance assessed and the response observed. In addition, the MOTIVATE studies excluded the use of raltegravir, etravirine and darunavir -which were all investigational agents at the time of study recruitment -and the use of tipranavir was limited. It is unclear whether the same similarity of outcome for genotypic versus phenotypic resistance assessment would be observed in more modern regimens using newer agents with less clinical outcome data for both methods of assessment. Related to this latter point, it is also unclear whether, for regimens involving newer agents than those in MOTIVATE, the same anticipated similarity of outcome between different genotypic algorithms would pertain.
Formal OBT scoring methods such as these, although essential to establish statistical associations with response, are of more limited value in the routine clinic to guide new regimen selection. In conclusion, however, the data from the g-wOBTSS and p-wOBTSS models suggest that using maraviroc with two fully active drugs from classes other than NRTIs -whether activity is assessed by genotype or phenotype -should result in undetectable viraemia in the majority of patients with CCR5-tropic virus. This is particularly true for those patients who present earlier in the disease/treatment process before a profound loss of CD4 + T-cells has occurred. The availability of new agents such as raltegravir, darunavir and etravirine makes it increasingly possible to construct such regimens for highly treatment-experienced patients without nucleoside analogue recycling.
